Matinas BioPharma Holdings, Inc. reported a significant decline in its financial performance for the fiscal year ended December 31, 2025, with a net loss of $10.3 million compared to a loss of $24.3 million in 2024. The company has not generated any revenue from product sales, as it remains focused on the development of its lead product candidate, MAT2203, an oral formulation of amphotericin B. The total research and development expenses plummeted to $85,000 from $11.4 million in the previous year, primarily due to a pause in the clinical development of MAT2203 and a substantial reduction in workforce, which saw an 80% cut in staff in late October 2024.
The company has faced challenges in its strategic partnerships, with negotiations for MAT2203's development and commercialization terminated in October 2024. This led to a reevaluation of its operational strategy, including a focus on conserving cash and exploring potential licensing or sale opportunities for MAT2203. The company is currently seeking to secure additional funding to support its operations, as it anticipates that its existing cash reserves will not be sufficient to cover expenses beyond the next twelve months.
Operationally, Matinas has paused its internal development of a pipeline utilizing its lipid nanocrystal (LNC) platform while it evaluates strategic alternatives. The company has engaged in discussions with potential partners for MAT2203, which is positioned for a Phase 3 registration trial pending the completion of a partnership transaction or additional capital raising. The FDA has agreed on the design of the ORALTO trial, which aims to evaluate MAT2203 in patients with invasive aspergillosis, but the trial's commencement is contingent on securing funding or a partnership.
As of December 31, 2025, Matinas had cash and cash equivalents of approximately $4 million, raising concerns about its ability to continue as a going concern. The company has indicated that it will need to raise substantial additional funding through various means, including equity offerings and potential collaborations, to support its ongoing operations and product development efforts. The financial outlook remains uncertain, with the company emphasizing the need for strategic partnerships to advance MAT2203 and its LNC platform technologies.
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings is a clinical-stage biopharmaceutical company developing lipid nanocrystal (LNC) platform-based therapies. Its lead product, MAT2203, is an oral antifungal designed to treat invasive fungal infections with improved safety and convenience. The company focuses on strategic partnerships, licensing, and advancing its pipeline through regulatory designations, targeting high-need markets such as invasive aspergillosis and cryptococcal meningitis.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.